Sean Park­er helps cre­ate a CRISPRed cell ther­a­py 2.0 play — and he’s got a high-pro­file set of lead­ers on the team

You can rack up one more high-pro­file de­but ef­fort in the wave of ac­tiv­i­ty form­ing around cell ther­a­py 2.0. It’s an­oth­er ap­peal­ing Bay Area group that’s at­tract­ed some of the top hands in the busi­ness to a mul­ti-year ef­fort to cre­ate a break­through. And they have $85 mil­lion in hand to make that first big step to the clin­ic.

To­day it’s Ken Drazan and the team at South San Fran­cis­co-based Ar­se­nal­Bio that are com­ing from be­hind the cur­tain for a pub­lic bow, backed by bil­lion­aire Sean Park­er and a col­lec­tion of in­vestors that in­cludes Beth Sei­den­berg’s new ven­ture in­vest­ment op­er­a­tion based in LA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER